Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JL 19001

Next Previous
Drug Profile

JL 19001

Alternative Names: JL-19001

Latest Information Update: 19 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JECHO Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B-cell lymphoma; Bladder cancer; Solid tumours

Most Recent Events

  • 25 Jun 2026 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (SC) (NCT07603479)
  • 25 Jun 2026 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (SC) (NCT07603479)
  • 22 May 2026 Jecho Biopharmaceuticals plans a phase I trial for Solid Tumors (Late-stage disease, Monotherapy, Combination therapy) or B-cell Non-Hodgkin Lymphoma (Second-line therapy or greater, Monotherapy, Combination therapy) in May 2026 (SC, Injection) (NCT07603479)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top